Gland Pharma receives USFDA EIR for Dundigal Facility

Written by Ruchika Sharma Published On 2023-08-24T16:30:57+05:30 | Updated On 24 Aug 2023 4:31 PM IST

Gland Pharma receives USFDA EIR for Dundigal Facility

Hyderabad: Through a recent BSE filing, Gland Pharma has informed that the Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) indicating the closure of the inspection at its Dundigal Facility in Hyderabad.

USFDA had inspected the facility between 03rd July, 2023 to 14th July, 2023 and issued one 483 Observation.

Gland Pharma, a generic injectable-focused pharmaceutical company, was established in 1978 in Hyderabad. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.

gland pharmagland pharma newsUSFDAUSFDA inspectionDundigal Facility

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751